Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Quest Diagnostics, Inc (NYSE: DGX) closed at $188.99 up 1.94% from its previous closing price of $185.39. In other words, the price has increased by $1.94 from its previous closing price. On the day, 0.55 million shares were traded. DGX stock price reached its highest trading level at $189.23 during the session, while it also had its lowest trading level at $185.17.
Ratios:
For a deeper understanding of Quest Diagnostics, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 66.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.27. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 1.09. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.79.
On April 02, 2025, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $195.
Citigroup Downgraded its Buy to Neutral on March 04, 2025, while the target price for the stock was maintained at $185.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 26 ’25 when PREVOZNIK MICHAEL E bought 227 shares for $188.13 per share.
PREVOZNIK MICHAEL E sold 28,288 shares of DGX for $5,293,313 on Sep 23 ’25. The SVP & General Counsel now owns 38,117 shares after completing the transaction at $187.12 per share. On Sep 24 ’25, another insider, PREVOZNIK MICHAEL E, who serves as the SVP & General Counsel of the company, sold 175 shares for $187.02 each. As a result, the insider received 32,729 and left with 38,117 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DGX now has a Market Capitalization of 21133512704 and an Enterprise Value of 27316512768. As of this moment, Quest’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.60, and their Forward P/E ratio for the next fiscal year is 18.26. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.01 while its Price-to-Book (P/B) ratio in mrq is 2.93. Its current Enterprise Value per Revenue stands at 2.596 whereas that against EBITDA is 13.273.
Stock Price History:
The Beta on a monthly basis for DGX is 0.56, which has changed by 0.21732688 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, DGX has reached a high of $187.96, while it has fallen to a 52-week low of $146.17. The 50-Day Moving Average of the stock is 5.99%, while the 200-Day Moving Average is calculated to be 10.96%.
Shares Statistics:
For the past three months, DGX has traded an average of 979.78K shares per day and 766540 over the past ten days. A total of 112.00M shares are outstanding, with a floating share count of 111.28M. Insiders hold about 0.49% of the company’s shares, while institutions hold 98.24% stake in the company. Shares short for DGX as of 1757894400 were 4421542 with a Short Ratio of 4.51, compared to 1755216000 on 4031308. Therefore, it implies a Short% of Shares Outstanding of 4421542 and a Short% of Float of 4.5100003.
Dividends & Splits
According to the company, the forward annual dividend rate for DGX is 3.10, from 3.1 in the trailing year. Against a Trailing Annual Dividend Yield of 0.016721506. The stock’s 5-year Average Dividend Yield is 1.87. . The current Payout Ratio is 39.15% for DGX, which recently paid a dividend on 2025-07-07 with an ex-dividend date of 2025-10-03. Stock splits for the company last occurred on 2005-06-21 when the company split stock in a 2:1 ratio.
Earnings Estimates
Investors are keenly observing as 14.0 analysts analyze and rate . The current performance of Quest Diagnostics, Inc (DGX) in the stock market.The consensus estimate for the next quarter is $2.42, with high estimates of $2.5 and low estimates of $2.35.
Analysts are recommending an EPS of between $9.81 and $9.67 for the fiscal current year, implying an average EPS of $9.75. EPS for the following year is $10.36, with 17.0 analysts recommending between $10.69 and $9.8.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $2.73B this quarter.It ranges from a high estimate of $2.76B to a low estimate of $2.71B. As of . The current estimate, Quest Diagnostics, Inc’s year-ago sales were $2.49BFor the next quarter, 12 analysts are estimating revenue of $2.72B. There is a high estimate of $2.74B for the next quarter, whereas the lowest estimate is $2.69B.
A total of 16 analysts have provided revenue estimates for DGX’s current fiscal year. The highest revenue estimate was $10.93B, while the lowest revenue estimate was $10.82B, resulting in an average revenue estimate of $10.86B. In the same quarter a year ago, actual revenue was $9.87BBased on 16 analysts’ estimates, the company’s revenue will be $11.24B in the next fiscal year. The high estimate is $11.38B and the low estimate is $11.12B.
